Strontium should no longer be used for osteoporosis treatment, warns European Agency

Published on January 19, 2014 at 1:44 AM · No Comments

All persons taking strontium supplements are warned that significant risks have been identified. Strontium drugs are not approved for treatment of osteoporosis in the United States. Now, the Risk Assessment Committee of the European Medicines Agency recommended that strontium should no longer be used to treat osteoporosis in Europe. The drugs Protelos/Osseor were specifically named as brand names for strontium ranelate.

Strontium citrate is commonly used in over-the-counter bone health supplements in the United States. American consumers should be especially concerned because more strontium is taken into the body from strontium citrate than from a similar amount of Protelos/Osseor.

The European Agency noted excessive numbers of serious heart problems (including heart attacks) along with blood clots or blockages of blood vessels. The report went on to state, "In addition, Protelos/Osseor is associated with a number of other risks, such as serious skin reactions, disturbances in consciousness, seizures (fits), liver inflammation and reduced number of blood cells."

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post